Understanding how bacteria resist new antibacterial treatments
Identifying Mechanisms of Resistance to Pathogen-Specific Antibacterial Antisense Compounds and Strategies to Circumvent Them
This study is looking at how some tough bacteria become resistant to new treatments called PPMOs, and it aims to find out how these treatments can still work against those bacteria, which could help patients with stubborn infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11117793 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which certain bacteria, particularly multidrug-resistant strains, develop resistance to a new class of antibacterial agents known as peptide-phosphorodiamidate morpholino oligomers (PPMOs). By using advanced techniques, the researchers aim to identify how these PPMOs can effectively target and kill harmful bacteria while overcoming resistance. The study will involve laboratory experiments and animal models to assess the effectiveness of PPMOs against various bacterial pathogens. Patients with infections caused by resistant bacteria may benefit from the insights gained in this research.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include patients suffering from infections caused by multidrug-resistant bacteria such as Acinetobacter baumannii.
Not a fit: Patients with infections caused by non-resistant bacteria may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown that PPMOs can effectively kill various bacterial pathogens, indicating a promising approach in combating antibiotic resistance.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Greenberg, David Elihu — Ut Southwestern Medical Center
- Study coordinator: Greenberg, David Elihu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.